ABEO — Abeona Therapeutics Inc.

Summary of ABEO Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $5.8 million for the year ended December 31, 2025, comprising:
  • License and Other Revenues: $3.4 million, primarily from a clinical milestone related to Rett syndrome.
  • Net Product Revenue: $2.4 million from the first commercial treatment of ZivaSkin in December 2025.
• Cost of Sales: $1.5 million, mainly from the first ZivaSkin treatment and prior production costs.
• R&D Expenses: Decreased to $26.8 million from $34.4 million in 2024 due to the capitalizing of production costs post-approval.
• SG&A Expenses: Increased to $65 million, reflecting the transition to commercialization and associated personnel costs.
• Net Income: $71.2 million, or $1.034 per basic share, compared to a net loss of $63.7 million in 2024.
• Cash Position: $191.4 million as of December 31, 2025.

2. Strategic Updates and Business Highlights

• ZivaSkin Launch: Approved in April 2025, but commercial launch delayed until Q4 2025 due to sterility testing issues. The first patient was treated in December 2025.
• Patient Demand: Over 100 potentially eligible patients identified, with a growing pipeline as the company engages community physicians.
• Qualified Treatment Centers (QTCs): Four centers activated, with two treating patients. Plans to onboard five additional centers to enhance geographic reach.
• Market Access: Coverage established with major payers, including Medicaid and commercial insurers, facilitating patient access to ZivaSkin.

3. Forward Guidance and Outlook

• Patient Treatment Cadence: Expecting a steady increase in treatments as more QTCs come online, with a target of seven active centers by the end of 2026.
• Profitability Outlook: Achieving profitability is contingent on treating at least three patients per month. The company is optimistic about reaching this target based on current demand and operational improvements.
• R&D Spending: Anticipated to focus on registry studies and pipeline development, with a shift from R&D to SG&A as commercialization progresses.

4. Bad News, Challenges, or Points of Concern

• Treatment Speed Variability: Initial treatments have been slower than expected, with only two patients treated so far. The company acknowledges that patient throughput may vary significantly across QTCs.
• Sterility Testing Issues: Although resolved, the previous sterility testing challenges caused delays in product release and may impact future production consistency.
• Administrative Delays: The timeline from patient identification to treatment initiation is currently around four to five months, which the company aims to improve as processes become more efficient.

5. Notable Q&A Insights

• QTC Onboarding: The onboarding process for new QTCs is complex and can take several months, influenced by institutional bureaucracy and the need for comprehensive training.
• Patient and Physician Feedback: Limited feedback from treated patients so far, but initial reports indicate positive outcomes. The company is monitoring treatment durability and patient experiences.
• Reimbursement Challenges: While payers have established criteria, physicians have successfully navigated some restrictions, indicating a flexible approach to patient eligibility.
• Production Capacity: Current capacity is six patients per month, with plans to increase to ten by mid-2026, aligning with the ramp-up of QTCs.

Overall, Abeona Therapeutics is navigating a critical phase of its commercial launch for ZivaSkin, with early signs of demand and operational readiness, but faces challenges in treatment speed and administrative processes that could impact growth.